26 Therapeutics is a preclinical-stage biotechnology company developing small-molecule therapies for dry eye disease and other meibomian gland disorders. The company’s lead program is a topical, disease-modifying approach designed to restore meibomian gland function.
Employees
1-10This company has no org chart yet
This company has no teams yet
This company has no offices yet